Salesforce Ventures and Optum Ventures helped the healthcare network technology provider push its valuation above $1.6bn and its total funding to near $200m.

The identity verification platform developer was valued at $1.3bn in a round featuring Synchrony Financial, Citi Ventures and Wells Fargo Strategic Capital.

SoftBank Vision Fund 2 and Tencent have co-led the intellectual property management platform’s series E round, which reportedly valued it at over $1bn.

The kidney healthcare provider boosted its total funding to more than $220m in a round led by Alphabet's CapitalG subsidiary.

Tencent and Gilead Sciences took part in a round that will fund clinical trials for three of Vaccitech's vaccine product candidates.

OSF Healthcare Ventures contributed to a $102m series D round for Inflammatix, a developer of diagnostics systems for detecting infections.

Fidelity Management & Research has joined new and returning investors to back the website creation platform developer’s latest round at a $10bn valuation.

D1 Capital Partners has led a $102m series D round for Inflammatix, whose existing shareholders include Stanford-StartX Fund.

The spinout’s technology was fundamental to Oxford’s covid vaccine, prompting OSI and Future Planet Capital to back a $168m round.

The database software provider more than doubled its valuation to nearly $5.8bn in a series E round that boosted its cash on hand to about $500m.